Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Medi & Gene currently has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These are assigned to 2 distinct examiners but are located within 1 distinct art unit. DABKOWSKI, ERINNE R is the busiest examiner with 1 pending office action, which accounts for one of the 2 pending office actions currently active for the company.
The involvement of 2 distinct examiners within 1 distinct art unit suggests that while the technological focus is narrow, the company must still navigate the individual styles of 2 different officials. Since DABKOWSKI, ERINNE R only manages 1 pending office action, the workload is evenly distributed between the 2 distinct examiners. This structure allows for a focused prosecution strategy within a single art unit while still requiring engagement with separate examiners.
For the practitioner, having 2 pending office actions in 1 distinct art unit means that the procedural rules and examination standards are likely consistent across both cases. However, the presence of 2 distinct examiners, including DABKOWSKI, ERINNE R with 1 pending action, necessitates a personalized approach for each matter. The 2 pending office actions represent the current scope of the company's active filings in this specific technology area.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| §103 only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DABKOWSKI, ERINNE R | 1 | 55.8% | +68.7% |
| ESPINOSA, CLAUDIA EDILMA | 1 | 50.9% | +56.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18258578 | NOVEL PEPTIDE AND USE THEREOF | DABKOWSKI, ERINNE R | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18258577 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING ALCOHOLIC AND NONALCOHOLIC FATTY LIVER DISEASE | ESPINOSA, CLAUDIA EDILMA | 4d overdue |
| 18258578 | NOVEL PEPTIDE AND USE THEREOF | DABKOWSKI, ERINNE R | — |
| Art Unit | Apps |
|---|---|
| 1654 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18258578 | NOVEL PEPTIDE AND USE THEREOF | DABKOWSKI, ERINNE R | 1654 | §101DP | Final Rejection | — | Pending | Jun 21, 2023 |
| 18258577 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING ALCOHOLIC AND NONALCOHOLIC FATTY LIVER DISEASE | ESPINOSA, CLAUDIA EDILMA | 1654 | §103 | Non-Final OA | 4d overdue | Pending | Jun 21, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMedi & Gene has 2 pending office actions as of October 2026, spread across 1 art units and 2 examiners.
Erinne R Dabkowski has the most, with 1 of Medi & Gene's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
